ArticleFrontiers in immunology2026

The real-world safety profile of enfortumab vedotin with or without pembrolizumab: insights from a comparative analysis of FAERS.

Heng Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.